Meningococcal Vaccine (Group A, C, Y & W-135) + Diphtheria Toxoid

Information about Meningococcal Vaccine (Group A, C, Y & W-135) + Diphtheria Toxoid

Meningococcal vaccine (group a, c, y & w-135) + diphtheria toxoid uses

Meningococcal Vaccine (Group A, C, Y & W-135)+Diphtheria Toxoid is used to prevent Meningococcal disease.

How meningococcal vaccine (group a, c, y & w-135) + diphtheria toxoid works

This contains Meningococcal Polysaccharides of serogroups A, C, Y, and W-135 antigens. It also contains diphtheria toxoid protein, that acts as a carrier for the individual serogroup antigens. This vaccine helps develop immunity by initiating a mild infection. This type of infection does not cause illness but stimulates the body's immune system to produce antibodies (proteins) to protect against any future infections.

Common side effects of meningococcal vaccine (group a, c, y & w-135) + diphtheria toxoid

Available Medicine for Meningococcal Vaccine (Group A, C, Y & W-135) + Diphtheria Toxoid

Menactra
₹5700
Sanofi India Ltd
1 variant(s)

Expert advice for Meningococcal Vaccine (Group A, C, Y & W-135) + Diphtheria Toxoid

Meningococcal Vaccine (Group A, C, Y & W-135) + Diphtheria Toxoid is used for active immunization to prevent meningococcal disease in individuals 9 months through 55 years of age.
In children 9 through 23 months of age, Meningococcal Vaccine (Group A, C, Y & W-135) + Diphtheria Toxoid is given as a 2-dose series at least three months apart.
In individuals 2 through 55 years of age, it is given as a single dose.